Full Press Release Details
"We are very pleased with this outcome, as it reaffirms the validity of these important patents," said David J. Scott , senior vice president, general counsel and secretary at Amgen. "This closes this matter and allows Amgen to continue to focus on bringing innovative therapies to patients with grievous illnesses."
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com .
Contact: Amgen Thousand Oaks Christine Regan : (805) 447-5476 (media) Arvind Sood : (805) 447-1060 (investors)